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tively). The SHRSP group had 12-fold higher levels of total aortic reactive oxygen species
(ROS) assessed by 8-iso-PGF2α, and 4-fold increase in superoxide content assessed by
hydroethidine staining of the aortic media. Both drugs significantly reduced ROS and
NAD(P)H oxidase essential subunit p22phox and its activity (P<0.05), whereas p-Akt,
eNOS, and the contractile-type smooth muscle myosin heavy chain SM2 were signifi-
cantly increased in SHRSP aorta (P<0.01). In addition, E4177 was more effective at
inducing VSMC differentiation by a 43% reduction of ROS through the downregulation of
NAD(P)H oxidase activity, and the upregulation of p-Akt by 27%, eNOS by 32%, and
SM2 by 34% compared with cilazapril respectively (P<0.05). Conclusions- An ACE
inhibitor and an AT1 receptor antagonist inhibited VSMC dedifferentiation through the
reduction of ROS by inhibiting NAD(P)H oxidase, and the upregulation of eNOS and Akt
in SHRSP aorta; suggesting that, in contrast to the results from in vitro experiments,
eNOS and Akt activation through the inhibition of AT1 receptor might be crucial determi-
nants for VSMC differentiation in hypertension in vivo.
1161-173 Stromelysin-1 (MMP-3) Gene 5A/6A Promoter 
Polymorphism Is Associated With Blood Pressure in a 
Community Population
John Beilby, Joseph Hung, Caroline Chapman, Brendan McQuillan, Peter Thompson, Sir 
Charles Gairdner Hospital, Perth, Australia, PathCentre QEII Medical Center, Perth, 
Australia
Background: Vascular remodelling of large and small arteries contributes to the devel-
opment of hypertension. Stromelysin-1, a member of the matrix metalloproteinase
(MMP) family may contribute to arterial remodelling. The expression of stromelysin-1
gene is partly regulated by a common polymorphism in the promoter region of either five
or six consecutive adenosine bases (5A/6A) that alter transcription factor binding.
Methods: A cross-sectional study of 1,111 randomly selected community subjects (553
males and 558 females), age 27-77 years, who were assessed for conventional cardio-
vascular risk factors and the stromelysin-1 5A-1171/6A genotype. Mean common carotid
intima-medial wall thickness (IMT) and presence of plaque was determined by carotid
ultrasound.
Results: The frequency of the stromelysin-1 -1171/5A allele was 0.45. Univariate analy-
sis demonstrated an association between the stromelysin-1 5A-1171/6A genotype and
blood pressure in the whole population. Multivariate analysis showed an independent
association between the stromelysin-1 genotype and systolic and diastolic blood pres-
sure (both P<0.005) in the whole sample. When the population was split by smoking sta-
tus, an independent association with systolic blood pressure (P<0.0001) and diastolic
blood pressure (P=0.006) was present only in smokers. Subjects who smoked and car-
ried the 5A/5A genotype had a higher mean systolic (+6.0 mmHg) and diastolic (+2.5
mmHg) blood pressure compared to 5A/6A and 6A/6A carriers. The association between
the stromelysin-1 genotypes and blood pressure was recessive with the effect only seen
with the 5A/5A genotype. Multivariate analysis in the whole population showed there was
no association with mean IMT (P=0.42) or the likelihood of carotid plaque formation
(P=0.08).
Conclusions: In this large randomly selected, cross-sectional population, the 5A/5A
variant in the stromelysin-1 gene promoter was independently associated with increased
blood pressure in the whole population and in smokers but was not associated with either
increased carotid IMT or plaque formation.
1161-174 Pulse Pressure and Interactions Between 
Polymorphisms in the Angiotensin II Type 1 Receptor 
and Uncoupling Protein 1 Genes in Hypertensive Hong 
Kong Chinese
Yu-Jing Fang, Cai-Xia Li, Ji-Qian Fang, G Neil Thomas, Brian Tomlinson, Chinese 
University of Hong Kong, Hong Kong, People's Republic of China, Sun Yat-Sen 
University, Guangzhou, People's Republic of China
Background: Hypertension and obesity are strongly inter-related and have multifactorial
genetic and environmental components. The angiotensin II type 1 receptor (AT1R) is
involved in the regulation of blood pressure and polymorphisms in this gene have been
implicated in the development of hypertension. The uncoupling protein 1 (UCP1) is solely
expressed in brown adipose tissue and genetic polymorphisms affecting this may be
associated with obesity. The present study was performed to assess the contribution of
polymorphisms of these two genes on blood pressure or obesity parameters in a family
study.
Methods: We studied members of 96 families with a hypertensive proband, including 282
siblings, of which 133 were hypertensive and 144 were obese. Blood pressure, pulse
pressure, body mass index (BMI) and waist:hip ratio (WHR) were recorded for each sib-
ling. The AT1R gene A1166C polymorphism and the UCP1 gene A-3826G polymorphism
were identified with polymerase chain reaction based RFLP protocols. A multi-level
mixed linear model for quantitative trait locus (QTL) analysis was applied to identify
whether these genetic polymorphism loci were related to blood pressure, pulse pressure
or body weight.
Results: No significant association was found between the AT1R and UCP1 gene poly-
morphisms and systolic or diastolic blood pressure. Age and the BMI/WHR ratio were
strongly related to the systolic blood pressure (p<0.0001), diastolic blood pressure
(p<0.0001) and pulse pressure (p=0.0003). Gender was only related to pulse pressure
(p=0.0003). For the AT1R and UCP1 gene polymorphisms, the QTL analysis showed that
the AT1R gene A1166C polymorphism was related to pulse pressure after adjustment for
age, gender and BMI/WHR ratio (p=0.038). A significant gene-gene interaction for pulse
pressure was found between the two gene polymorphisms after adjustment for age, gen-
der and BMI/WHR ratio (p=0.031).
Conclusions: Genetic variation at the AT1R gene locus may modify the risk for developing
abnormal pulse pressure. An interaction between the AT1R genotype and UCP1 geno-
type suggests these loci may be important in determining abnormal blood pressures in
relation to obesity.
1161-175 Platelet-Derived Vascular Endothelial Growth Factor in 
Patients With Hypertension: Relationship to Platelet 
Activation and Plasma Indices of Angiogenesis
Sunil K. Nadar, Graham J. Caine, Andrew D. Blann, Gregory YH Lip, City Hospital, 
Birmingham, United Kingdom
Aims: Platelet activation is an important part of the pathogenesis of complications in
hypertension (HT). Hypertension is also associated with abnormal angiogenesis. We
hypothesise a relationship of platelet derived Vascular Endothelial Growth Factor (VEGF)
to plasma markers of angiogenesis (VEGF, Angiopoietin (Ang)-1 and 2, and Ang receptor
Tie-2) and platelet activation (soluble P-selectin) in hypertension.
Methods: We studied 199 (151 male, mean age 67+ 9 years) patients with HT and 59
normotensive controls( 41 male; mean age 68+11 years). Plasma levels of angiogenesis
such as VEGF, Ang-1, and Ang2, and Tie-2 were determined by ELISA. Platelet derived
VEGF was measured by lysing a fixed number of platelets, and measuring the levels in
the lysate so obtained.
Results: Plasma indices were abnormal in HT versus controls [Table1]. Platelet derived
VEGF did not vary with the use of aspirin or antihypertensive agents. Platelet derived
VEGF correlated with plasma levels of VEGF( Spearmans r=0.257, p=0.001), Ang 1
(r=0.307, p=0.001) and Tie 2 (r=0.19 p=0.007), but not with soluble p-selectin.
Conclusions: Hypertensive patients have raised platelet derived VEGF which correlates
with the plasma levels of VEGF and Ang-1. This suggests a role for platelets in the abnor-
mal angiogenesis that is seen in hypertension
1161-176 Carvedilol Reduces Serum Concentration of DNA-
Damage Biomarker 8-Hydroxydeoxyguanosine in 
Human Hypertension
Juyong Lee, Mejeong Lee, Jung-Wook Kim, Jin-Geun Jang, Yoon-Suck Choi, Sang-Sig 
Cheong, Gangneung Asan Hospital, Gangneung-si, South Korea
Background: Oxidative DNA damage due to reactive oxygen species(ROS) has been
implicated in cardiovascular diseases. Deoxyguanosine is one of the constituents of DNA
and when it is oxidized, it is altered into 8-OHdG. The serum concentration of the DNA
repair product 8-OHdG has been proposed as a noninvasive biomarker of oxidative DNA
damage in human in vivo. Carvedilol has shown to have antioxidant actions in patients by
reduction of anti-oxidized LDL antibodies and to reduce ROS in normal human subjects.
However, there has been no data that carvedilol reduce DNA damage in human hyper-
tension. Methods: Seventeen newly diagnosed hypertension patients (mean age
=51±11, male/female=11/6) who have not taken antihypertensive medication previously
volunteered for the study. Fasting blood sample were collected at baseline in tubes with
EDTA as an anticoagulant. The subjects were given 12.5 or 25 mg of carvedilol PO once
a day for 2 months. Two months later, another blood sample was collected as above. Age
and sex matched control subjects (n=22, mean age =45±12, male/female=14/8), not
given any drugs, also had 2 samples taken 2 months apart. None of the subjects were on
any medications, including NSAIDs, Vitamin E, or other antioxidants. Serum 8-OHdG
was measured with ELISA method. High sensitivity C-reactive protein (hs-CRP) was also
checked two times. There were no statistical differences in smoking, diabetes, and total
cholesterol level between hypertension and control group. Results: In the hypertension
group, DNA damage biomarker 8-OHdG at baseline was 9.07±4.23 ng/ml (mean±SD).
After carvedilol administration, it fell to 5.74±3.89 ng/ml (p=0.002). In the control group,
the 8-OHdG concentrations were 3.41±2.03, 3.01±2.65 ng/ml at baseline and 2 months
later, respectively (p=NS). The baseline 8-OHdG was higher in the group of hypertension
than in control(p=0.001). hs-CRP had no significant difference before and after carvedilol
treatment in the hypertension group( 0.21±0.51, 0.19±0.37 mg/dl). Conclusion: DNA
damage due to ROS occurs more in hypertension patients than in normal blood pressure
people. Carvedilol may significantly reduce DNA damage in hypertension patients.
1161-177 Modulatory Effect of Inflammation on Blood Pressure 
Reduction Following Therapeutic Lifestyle Change via 
Cardiac Rehabilitation and Exercise Training
Richard V. Milani, Carl J. Lavie, Ochsner Clinic Foundation, New Orleans, LA
Background: Inflammation promotes the development and progression of atherosclerosis
and is associated with several traditional CV risk factors including hypertension, diabe-
tes, and dyslipidemia. We evaluated the impact of inflammation on improvement in risk
factors following 12 weeks (36 sessions) of therapeutic lifestyle change (TLC) via cardiac
rehabilitation and exercise training (CRET) in 635 patients (mean age 64.6 ±10.7 years)
4-6 weeks following a major CHD event.
Methods: Patients were dichotomized based upon baseline median hs-CRP (median =
3.2 mg/L) values. At baseline there were no differences in age, gender, systolic and dias-
Controls (n=59) Hypertensive (n=199) p-value
SBP (mmHg) 130(9) 147(22) 0.001
DBP (mmHg) 80 (9) 80(11) 0.9
s P-selectin (ng/ml) 77(38-110) 150(106-213) <0.001
VEGF (ng/ml) 500(42-7750) 1500(30-100000) <0.001
Ang-1 (ng/ml) 10(6-60) 700(250-1300) <0.001
Ang-2 (ng/ml) 1.8(0.5-3.0) 1.8(1.1-3.5) 0.01
Platelet VEGF (ng/ml) 30 (10-200) 600(50-3000) <0.001
